Interní Med. 2017; 19(4): 179-185 | DOI: 10.36290/int.2017.032

Why are patients with peripheral artery disease dying unnecessarily for ischemic heart disease?

doc. MUDr. Jan Piťha, CSc.
Interní klinika, FN Motol, Praha
Laboratoř pro výzkum aterosklerózy, Centrum experimentální medicíny,
Institut klinické a experimentální medicíny, Praha

Peripheral artery disease (PAD) is caused mostly by atherosclerotic process similarly as to ischemic heart disease (IHD). Since theatherosclerotic process is diffuse, not surprisingly, other arterial blood vessels are frequently affected. The fate of patients with PADis to be changed by intervention atherosclerosis everywhere in all locations but mainly in coronary arteries. When PAD is diagnosed,it is necessary to immediately get under control four basic risk factors – smoking, diabetes mellitus, dyslipidemia and hypertension– as much as possible and as soon as possible to prevent often fatal manifestation of IHD. The main goal of PAD treatmentis, therefore, not only to relieve claudications and/or to prevent trophic changes in lower limbs, but to minimize the overall risk ofserious cardiovascular events. The cornerstone of this approach are lifestyle measurements – abstinence from smoking, adequatephysical activity and appropriate nutrition. In almost all cases in patients at such high risk, statin therapy should be implemented,and potentiated with ezetimibe; in selected patients with PAD fenofibrate could be considered. Another important steps are thecontrol of hypertension and diabetes mellitus. New treatment modalities including inhibitors of proprotein convertase subtilisinkexin 9, LDL apheresis, rheoferesis can be also important to improve status for high-risk patients.

Keywords: peripheral artery disease, ischemic heart disease, risk factor, management

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J. Why are patients with peripheral artery disease dying unnecessarily for ischemic heart disease? Interní Med. 2017;19(4):179-185. doi: 10.36290/int.2017.032.
Download citation

References

  1. Sigvant B, Hasvold P, Kragsterman B, et al. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. J Vasc Surg. 2017 Apr 19. pii: S0741-5214(17)30393-2. doi: 10.1016/j.jvs.2017.01.067. [Epub ahead of print] Go to original source...
  2. Kullo IJ, Rooke TW. CLINICAL PRACTICE. Peripheral Artery Disease. N Engl J Med. 2016; 374(9): 861-871. Go to original source...
  3. Nakamura E, Sato Y, Iwakiri T, et al. Asymptomatic Plaques of Lower Peripheral Arteries and Their Association with Cardiovascular Disease: An Autopsy Study. J Atheroscler Thromb. 2017 Mar 31.doi: 10.5551/jat.39669. [Epub ahead of print] Go to original source... Go to PubMed...
  4. Berger JS, Ladapo JA. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2017; 69(18): 2293-2300. Go to original source...
  5. Henningfield, JE, Shiffman, S, Ferguson, SG, et al. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther, 2009; 123: 1-16. Go to original source...
  6. Karanja N, Lancaster KJ, Vollmer WM, et al. Acceptability of sodium-reduced research diets, including the Dietary Approaches To Stop Hypertension diet, among adults with prehypertension and stage 1 hypertension. J Am Diet Assoc, 2007; 107: 1530-1538. Go to original source... Go to PubMed...
  7. Barry E, Roberts S, Oke J, et al. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ. 2017; 356: i6538. Go to original source... Go to PubMed...
  8. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-1486. Go to original source...
  9. Estruch R, Ros, E, Salas-Salvadó J, Covas MI, et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med, 2013; 368: 1279-1290. Go to original source...
  10. Ruiz-Canela M, Estruch R, Corella D, et al. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA. 2014; 311(4): 415-417. Go to original source... Go to PubMed...
  11. Soška V, Vaverková H, Vrablík M, et al. Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011 | Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. Vnitrni Lekarstvi, 2013; 59: 120-126. Go to PubMed...
  12. Rajamani K, Colman PG, Li LP, et al. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet, 2009; 373: 1780-1788. Go to original source...
  13. Banach M, Nikolic D, Rizzo M, et al. IMPROVE-IT: what have we learned? Curr Opin Cardiol. 2016; 31(4): 426-433. Go to original source... Go to PubMed...
  14. Kampangkaew J, Pickett S, Nambi V. Advances in the management of dyslipidemia. Curr Opin Cardiol. 2017; 32(4): 348-355. Go to original source... Go to PubMed...
  15. Bláha V, Bláha M, Lánská M, et al. [Position of lipoprotein apheresis in present]. Vnitr Lek. 2015; 61(11): 958-964. Go to PubMed...
  16. Poredos P, Jezovnik MK. Is aspirin still the drug of choice for management of patients with peripheral arterial disease? Vasa, 2013; 42: 88-95. Go to original source... Go to PubMed...
  17. Mohler ER 3rd. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both? Catheter Cardiovasc Interv, 2009; 74(Suppl 1): S1-6. Go to original source... Go to PubMed...
  18. Weiss N. A critical review on the use of lipid apheresis and rheopheresis for treatment of peripheral arterial disease and the diabetic foot syndrome. Semin Dial. 2012; 25(2): 220-227. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.